AZN News and Press, AstraZeneca PLC From 02/09/24

A look at the top 10 most actives in the United States NanoString Technologies Inc. (NSTG) rose 118.4% to $0.1162 on volume of 394,556,402 shares U Power Limited (UCAR) rose 45.5% to $0.0959 on volume of 274,384,293 shares Palantir Technologies Inc. Class A (PLTR) rose 3.9% to $24.51 on v...

2024-02-09 02:51:35 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2024-02-08 16:15:30 ET Image source: The Motley Fool. AstraZeneca Plc (NASDAQ: AZN) Q4 2023 Earnings Call Feb 08, 2024 , 6:45 a.m. ET Andy Barnett Continue reading For further details see: AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript

A look at the top 10 most actives in the United States NanoString Technologies Inc. (NSTG) rose 164.5% to $0.1407 on volume of 378,097,862 shares U Power Limited (UCAR) rose 55.6% to $0.102517 on volume of 264,170,127 shares Palantir Technologies Inc. Class A (PLTR) rose 5.8% to $24.965 o...

2024-02-08 15:10:05 ET AstraZeneca PLC (AZN) Q4 2023 Earnings Conference Call February 8, 2024, 06:45 AM ET Company Participants Andy Barnett - Head, IR Pascal Soriot - CEO Aradhana Sarin - CFO David Fredrickson - EVP, Oncology Business Susan Galbraith - ...

2024-02-08 12:56:29 ET Summary AstraZeneca reported $45.8bn in revenues for 2023, a 6% gain from the previous year on a CER basis. EPS of $7.26 was up 15% year-over-year. The company's oncology division accounted for 37% of total revenues, with several blockbuster drugs driving gr...

2024-02-08 09:23:00 ET U.S. stock index futures on Thursday pointed to a mixed open, after some slightly hawkish labor market data came in. The benchmark S&P 500 ( SP500 ) will be on watch, with the index just a whisker away from hitting the historic 5,000 points mark for the fi...

2024-02-08 08:53:33 ET More on Pre-market losers & stocks. Peraso Inc. (PRSO) Q3 2023 Earnings Call Transcript Tenax surges after patent win for heart failure therapy Peraso to raise ~$4M through underwritten public offering of shares and warrants Financi...

2024-02-08 08:35:27 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Pioneering Precision Medicine Ionis angioedema drug shows positive results in Phase 3 trial FDA approves AstraZeneca, Ionis drug for ATTRv-PN Seeking Alpha’s Quant Rating on Io...

2024-02-08 07:09:07 ET More on AstraZeneca AstraZeneca's Q4 Earnings: Recognizing The Underrated Gem's Growth Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca beats t...